Connect with us

Headlines

There’s a Problem with the Luxottica-Essilor Merger

The combined organization is plagued by infighting.

mm

Published

on

Things aren’t going so well at EssilorLuxottica SA, the company created by the merger of Essilor International and Luxottica Group, Bloomberg reports.

The organization is plagued by infighting among its leadership. Its share price is down 22 percent since the October merger, Bloomberg notes.

Luxottica founder Leonardo Del Vecchio says Essilor’s leaders aren’t sticking to the agreed-upon terms of corporate governance, according to Bloomberg. He’s the combined company’s largest shareholder and serves as its executive chairman.

Meanwhile, Essilor’s Hubert Sagnieres, who serves as vice chairman of the merged organization, says Del Vecchio has staged a “de facto attempt to take control of the new group.” He claims Del Vecchio has made false accusations as to the group’s governance and management.

Del Vecchio previously told Le Figaro, a French newspaper, that Sagnieres failed to communicate with him on matters such as filling key management jobs.

“He has acted as if Essilor bought Luxottica,” Del Vecchio was quoted saying.

Advertisement

The companies completed their merger in October.

Following the contribution by Delfin, at the time the majority shareholder of Luxottica, of its 62.42 percent stake in Luxottica to Essilor on Oct. 1, Essilor became the parent company of Luxottica and was renamed EssilorLuxottica.

Read more at Bloomberg

Since launching in 2014, INVISION has won 21 international journalism awards for its publication and website. Contact INVISION's editors at editor@invisionmag.com.

Advertisement

SPONSORED VIDEO

SPONSORED BY HOYA

Hoya: The Right Lenses for Sun Protection

Eye safety has never been more important--or fashionable. Check out Hoya's Serenity photochromic and Coppertone(R) polarized lens collections, just in time for summer!

Promoted Headlines

Headlines

Vision Biotech Firm Changes Name

The company focuses on gene therapy.

mm

Published

on

Ophthotech Corp., a biotech company focused on diseases of the eye, announced that it is changing its name to IVERIC bio Inc.

The change is part of a “transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases with unmet medical needs,” the company said in a press release.

The firm will trade on the Nasdaq Global Select Market under the new ticker symbol “ISEE.” Its new corporate website at www.ivericbio.com.

“We are excited about our re-branding and corporate name change reflecting our transition to a gene therapy focused company developing treatments for patients with orphan inherited retinal diseases,” stated Glenn P. Sblendorio, CEO and president of IVERIC bio. “We are executing a strategy that leverages our retinal expertise and provides a clear path forward with multiple orphan IRD gene therapy programs.

“We believe this is an important time for the Company as we advance our diversified pipeline of scientifically compelling gene therapy programs and explore new gene therapy opportunities for the treatment of orphan IRDs and generate value for our shareholders.”

Advertisement

Dr. Kourous A. Rezaei, chief medical officer of IVERIC bio,  said: “We believe that gene therapy is the ideal solution to treat patients with orphan inherited retinal diseases for which there are no treatment options available.

“Our goal is to partner with physicians to address this significant unmet medical need, prevent vision loss and transform the lives of our patients. We look forward to the exciting opportunities that lie ahead. Our clinical therapeutic programs continue to remain on track, with clinical data expected by the end of 2019 and 2020 for these programs. If data are positive for these programs, we may seek partnership opportunities for future clincal development.”

Continue Reading

Headlines

Eyewear Company Settles with VSP, Gets Reinstated in Network

VSP removed Aspex from its provider list in 2010.

mm

Published

on

RANCHO CORDOVA, CA – VSP Global and Aspex Eyewear Inc. announced that Aspex has agreed to pay a financial settlement to VSP Global.

Aspex Eyewear will be reinstated as an in-network frame provider under VSP’s vision care insurance policies.

Podcast: More Ways to Motivate Your Own Eyecare Business Team
INVISION Podcast

Podcast: More Ways to Motivate Your Own Eyecare Business Team

Podcast: Why Can’t We All Just Get Along?
INVISION Podcast

Podcast: Why Can’t We All Just Get Along?

Podcast: Try Not to Blink Talks About the Business of Cannabis, and Its Role in Modern Healthcare
Try Not to Blink

Podcast: Try Not to Blink Talks About the Business of Cannabis, and Its Role in Modern Healthcare

Financial terms of the settlement were not disclosed.

The settlement arises from several lawsuits filed by Aspex Eyewear against VSP and Marchon Eyewear, according to a joint statement from VSP and Aspex.

“While court rulings over several years have resulted in favorable decisions for VSP Global, we are nevertheless pleased with this agreement and the opportunity for our respective organizations to move forward,” said Thomas A. Fessler, chief legal counsel and general counsel of VSP Global.

Thierry Ifergan, executive vice president of Aspex Eyewear, said: “Aspex is happy to be reinstated as an in-network frame provider. We are excited to offer Aspex’s top fashion and innovative technologies to VSP’s members through their extensive network of eye care professionals.”

Advertisement

The Sacramento Business Journal has reported that VSP decided “to remove Aspex from its in-network provider list in 2010 after the Canadian eyewear company sued two VSP subsidiaries for patent infringement.”

Aspex then filed suit alleging “breach of contract, antitrust violations and unfair business practices” by VSP in connection with that decision, according to the Business Journal.

Continue Reading

Headlines

Optometry College Inaugurates President

He is the 13th person to serve in the role.

mm

Published

on

New England College of Optometry has inaugurated Dr. Howard B. Purcell as its president.

Purcell is the 13th president in the college’s 125 year history, according to a press release from the institution. He is a graduate of the program, continuing the legacy of his father, Saul Purcell, who graduated in 1954.

New England College of Optometry inaugurated Dr. Howard B. Purcell as its 13th president. Source: New England College of Optometry

The ceremony took place at the Edward Kennedy Institute for the U.S. Senate in Boston in a recreation of the U.S. Senate chamber. It was attended by over 200 people, including the president’s family, friends and former and current colleagues, student leaders, industry leaders and community representatives. Distinguished delegates included representatives from four optometry schools – Dr. Kevin Alexander (Marshall B. Ketchum University), Dr. Morris Berman (MCPHS), Dr. Mark Colip (Illinois College of Optometry) and Dr. David Heath (State University of New York College of Optometry).

Pano Yeracaris, MD, chairman of the board, said Purcell’s “enthusiasm, energy and commitment is matched by his vision and effectiveness as a leader.”

Cynthia P. Macdonald, great granddaughter of NECO founder August Klein, noted all the hats that Purcell must now wear.

“I know that each one of those hats will be woven from threads of knowledge and competence, care and compassion, diversity and inclusivity, respect and integrity,” Macdonald said. “These are the shining threads that together create the tapestry of the many generations of NECO family. The Klein Family Legacy is now entrusted to your care, Dr. Purcell, and I have no doubt it will be well tended.”

Purcell stepped into the role on July 1, 2018. Over the past nine months, he “has become indelibly connected to the NECO community,” according to the release.

Student Council President Monica Luo, class of 2020, described his immediate immersion into NECO.

“For an institution that feels so strongly about the creation and nurturing of meaningful bonds and relationships, President Purcell is the perfect fit,” Luo said. “In just his first few months, he made every effort to be present everywhere and to speak to everyone. … For every individual, he is open to listening and providing support. He is always present and always receptive.”

Purcell outlined his strategic priorities for the college to help “prepare today’s optometrists for tomorrow’s optometry.” His vision includes diversifying revenue; nurturing diversity, equity and inclusion; expanding continuing education and specialized degree programs; collaborating with industry; and finding ways to “best support and prepare our students for whatever changes may arise,” according to the release.

Continue Reading

Advertisement

Advertisement

Advertisement

Most Popular